Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Urinary Metabolites Diagnostic and Prognostic of Intrahepatic Cholangiocarcinoma.

Haznadar M, Diehl CM, Parker AL, Krausz KW, Bowman ED, Rabibhadana S, Forgues M, Bhudhisawasdi V, Gonzalez FJ, Mahidol C, Budhu A, Wang XW, Ruchirawat M, Harris CC.

Cancer Epidemiol Biomarkers Prev. 2019 Jul 29. doi: 10.1158/1055-9965.EPI-19-0453. [Epub ahead of print]

PMID:
31358519
2.

NELFE-Dependent MYC Signature Identifies a Unique Cancer Subtype in Hepatocellular Carcinoma.

Dang H, Pomyen Y, Martin SP, Dominguez DA, Yim SY, Lee JS, Budhu A, Shah AP, Bodzin AS, Wang XW.

Sci Rep. 2019 Mar 4;9(1):3369. doi: 10.1038/s41598-019-39727-9.

3.

Single-cell analysis reveals cancer stem cell heterogeneity in hepatocellular carcinoma.

Zheng H, Pomyen Y, Hernandez MO, Li C, Livak F, Tang W, Dang H, Greten TF, Davis JL, Zhao Y, Mehta M, Levin Y, Shetty J, Tran B, Budhu A, Wang XW.

Hepatology. 2018 Jul;68(1):127-140. doi: 10.1002/hep.29778. Epub 2018 May 9.

4.

Common Molecular Subtypes Among Asian Hepatocellular Carcinoma and Cholangiocarcinoma.

Chaisaingmongkol J, Budhu A, Dang H, Rabibhadana S, Pupacdi B, Kwon SM, Forgues M, Pomyen Y, Bhudhisawasdi V, Lertprasertsuke N, Chotirosniramit A, Pairojkul C, Auewarakul CU, Sricharunrat T, Phornphutkul K, Sangrajrang S, Cam M, He P, Hewitt SM, Ylaya K, Wu X, Andersen JB, Thorgeirsson SS, Waterfall JJ, Zhu YJ, Walling J, Stevenson HS, Edelman D, Meltzer PS, Loffredo CA, Hama N, Shibata T, Wiltrout RH, Harris CC, Mahidol C, Ruchirawat M, Wang XW; TIGER-LC Consortium.

Cancer Cell. 2017 Jul 10;32(1):57-70.e3. doi: 10.1016/j.ccell.2017.05.009. Epub 2017 Jun 22.

5.

A joint analysis of transcriptomic and metabolomic data uncovers enhanced enzyme-metabolite coupling in breast cancer.

Auslander N, Yizhak K, Weinstock A, Budhu A, Tang W, Wang XW, Ambs S, Ruppin E.

Sci Rep. 2016 Jul 13;6:29662. doi: 10.1038/srep29662.

6.

Inhibition of wnt/β-catenin Signaling in Hepatocellular Carcinoma by an Antipsychotic Drug Pimozide.

Fako V, Yu Z, Henrich CJ, Ransom T, Budhu AS, Wang XW.

Int J Biol Sci. 2016 Apr 28;12(7):768-75. doi: 10.7150/ijbs.14718. eCollection 2016.

7.

Three-dimensional Organotypic Culture Models of Human Hepatocellular Carcinoma.

Takai A, Fako V, Dang H, Forgues M, Yu Z, Budhu A, Wang XW.

Sci Rep. 2016 Feb 16;6:21174. doi: 10.1038/srep21174.

8.

Hepatic stellate cell and monocyte interaction contributes to poor prognosis in hepatocellular carcinoma.

Ji J, Eggert T, Budhu A, Forgues M, Takai A, Dang H, Ye Q, Lee JS, Kim JH, Greten TF, Wang XW.

Hepatology. 2015 Aug;62(2):481-95. doi: 10.1002/hep.27822. Epub 2015 Apr 28.

9.

Letter to the editor: the heart of a leader.

Budhu A.

Nurs Sci Q. 2015 Apr;28(2):174. doi: 10.1177/0894318415571602. No abstract available.

PMID:
25805396
10.

Integrative genomics identifies YY1AP1 as an oncogenic driver in EpCAM(+) AFP(+) hepatocellular carcinoma.

Zhao X, Parpart S, Takai A, Roessler S, Budhu A, Yu Z, Blank M, Zhang YE, Jia HL, Ye QH, Qin LX, Tang ZY, Thorgeirsson SS, Wang XW.

Oncogene. 2015 Sep 24;34(39):5095-104. doi: 10.1038/onc.2014.438. Epub 2015 Jan 19.

11.

Integrative genomic and transcriptomic characterization of matched primary and metastatic liver and colorectal carcinoma.

Roessler S, Lin G, Forgues M, Budhu A, Hoover S, Simpson RM, Wu X, He P, Qin LX, Tang ZY, Ye QH, Wang XW.

Int J Biol Sci. 2015 Jan 1;11(1):88-98. doi: 10.7150/ijbs.10583. eCollection 2015.

12.

Deciphering cancer heterogeneity: the biological space.

Roessler S, Budhu A, Wang XW.

Front Cell Dev Biol. 2014 Apr 3;2:12. doi: 10.3389/fcell.2014.00012. eCollection 2014.

13.

Metabolic profiles are principally different between cancers of the liver, pancreas and breast.

Budhu A, Terunuma A, Zhang G, Hussain SP, Ambs S, Wang XW.

Int J Biol Sci. 2014 Aug 30;10(9):966-72. doi: 10.7150/ijbs.9810. eCollection 2014.

14.

The origin of cancer stem cells.

Dang HT, Budhu A, Wang XW.

J Hepatol. 2014 Jun;60(6):1304-5. doi: 10.1016/j.jhep.2014.03.001. Epub 2014 Mar 13. No abstract available.

15.

Integration of metabolomics and transcriptomics revealed a fatty acid network exerting growth inhibitory effects in human pancreatic cancer.

Zhang G, He P, Tan H, Budhu A, Gaedcke J, Ghadimi BM, Ried T, Yfantis HG, Lee DH, Maitra A, Hanna N, Alexander HR, Hussain SP.

Clin Cancer Res. 2013 Sep 15;19(18):4983-93. doi: 10.1158/1078-0432.CCR-13-0209. Epub 2013 Aug 5.

16.

High-throughput screening for identification of inhibitors of EpCAM-dependent growth of hepatocellular carcinoma cells.

Henrich CJ, Budhu A, Yu Z, Evans JR, Goncharova EI, Ransom TT, Wang XW, McMahon JB.

Chem Biol Drug Des. 2013 Aug;82(2):131-9. doi: 10.1111/cbdd.12146.

17.

Integrated metabolite and gene expression profiles identify lipid biomarkers associated with progression of hepatocellular carcinoma and patient outcomes.

Budhu A, Roessler S, Zhao X, Yu Z, Forgues M, Ji J, Karoly E, Qin LX, Ye QH, Jia HL, Fan J, Sun HC, Tang ZY, Wang XW.

Gastroenterology. 2013 May;144(5):1066-1075.e1. doi: 10.1053/j.gastro.2013.01.054. Epub 2013 Jan 31.

18.

Transforming the microenvironment: a trick of the metastatic cancer cell.

Budhu A, Wang XW.

Cancer Cell. 2012 Sep 11;22(3):279-80. doi: 10.1016/j.ccr.2012.08.018.

19.

Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma.

Oishi N, Kumar MR, Roessler S, Ji J, Forgues M, Budhu A, Zhao X, Andersen JB, Ye QH, Jia HL, Qin LX, Yamashita T, Woo HG, Kim YJ, Kaneko S, Tang ZY, Thorgeirsson SS, Wang XW.

Hepatology. 2012 Nov;56(5):1792-803. doi: 10.1002/hep.25890. Epub 2012 Aug 22.

20.

At the cancer steering wheel: defining key genomic drivers of liver cancer with next generation sequencing.

Budhu A, Wang XW.

J Hepatol. 2012 Jun;56(6):1412-4. doi: 10.1016/j.jhep.2011.12.024. Epub 2012 Jan 28. No abstract available.

21.

Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival.

Roessler S, Long EL, Budhu A, Chen Y, Zhao X, Ji J, Walker R, Jia HL, Ye QH, Qin LX, Tang ZY, He P, Hunter KW, Thorgeirsson SS, Meltzer PS, Wang XW.

Gastroenterology. 2012 Apr;142(4):957-966.e12. doi: 10.1053/j.gastro.2011.12.039. Epub 2011 Dec 24.

22.

MicroRNAs and Gastroenterological Cancers.

Budhu A, Wang XW.

Drug Discov Today Dis Mech. 2011 Winter;8(3-4):e95-e102. Epub 2011 Dec 11.

23.

Power play: scoring our goals for liver cancer with better GWAS study design.

Budhu A, Wang XW.

J Hepatol. 2011 Apr;54(4):823-4. doi: 10.1016/j.jhep.2010.10.035. Epub 2010 Dec 7. No abstract available.

24.

A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients.

Roessler S, Jia HL, Budhu A, Forgues M, Ye QH, Lee JS, Thorgeirsson SS, Sun Z, Tang ZY, Qin LX, Wang XW.

Cancer Res. 2010 Dec 15;70(24):10202-12. doi: 10.1158/0008-5472.CAN-10-2607.

25.

Association of TP53 mutations with stem cell-like gene expression and survival of patients with hepatocellular carcinoma.

Woo HG, Wang XW, Budhu A, Kim YH, Kwon SM, Tang ZY, Sun Z, Harris CC, Thorgeirsson SS.

Gastroenterology. 2011 Mar;140(3):1063-70. doi: 10.1053/j.gastro.2010.11.034. Epub 2010 Nov 19.

26.

Inflammatory and microRNA gene expression as prognostic classifier of Barrett's-associated esophageal adenocarcinoma.

Nguyen GH, Schetter AJ, Chou DB, Bowman ED, Zhao R, Hawkes JE, Mathé EA, Kumamoto K, Zhao Y, Budhu A, Hagiwara N, Wang XW, Miyashita M, Casson AG, Harris CC.

Clin Cancer Res. 2010 Dec 1;16(23):5824-34. doi: 10.1158/1078-0432.CCR-10-1110. Epub 2010 Oct 14.

27.

The clinical potential of microRNAs.

Budhu A, Ji J, Wang XW.

J Hematol Oncol. 2010 Oct 6;3:37. doi: 10.1186/1756-8722-3-37. Review.

28.

Let-7g targets collagen type I alpha2 and inhibits cell migration in hepatocellular carcinoma.

Ji J, Zhao L, Budhu A, Forgues M, Jia HL, Qin LX, Ye QH, Yu J, Shi X, Tang ZY, Wang XW.

J Hepatol. 2010 May;52(5):690-7. doi: 10.1016/j.jhep.2009.12.025. Epub 2010 Mar 1.

29.

MicroRNA expression, survival, and response to interferon in liver cancer.

Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S, Ambs S, Chen Y, Meltzer PS, Croce CM, Qin LX, Man K, Lo CM, Lee J, Ng IO, Fan J, Tang ZY, Sun HC, Wang XW.

N Engl J Med. 2009 Oct 8;361(15):1437-47. doi: 10.1056/NEJMoa0901282.

30.

MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival.

Mathé EA, Nguyen GH, Bowman ED, Zhao Y, Budhu A, Schetter AJ, Braun R, Reimers M, Kumamoto K, Hughes D, Altorki NK, Casson AG, Liu CG, Wang XW, Yanaihara N, Hagiwara N, Dannenberg AJ, Miyashita M, Croce CM, Harris CC.

Clin Cancer Res. 2009 Oct 1;15(19):6192-200. doi: 10.1158/1078-0432.CCR-09-1467. Epub 2009 Sep 29.

31.

Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells.

Ji J, Yamashita T, Budhu A, Forgues M, Jia HL, Li C, Deng C, Wauthier E, Reid LM, Ye QH, Qin LX, Yang W, Wang HY, Tang ZY, Croce CM, Wang XW.

Hepatology. 2009 Aug;50(2):472-80. doi: 10.1002/hep.22989.

32.

Translating the metastasis paradigm from scientific theory to clinical oncology.

Dong F, Budhu AS, Wang XW.

Clin Cancer Res. 2009 Apr 15;15(8):2588-93. doi: 10.1158/1078-0432.CCR-08-2356. Epub 2009 Apr 7.

33.

EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features.

Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY, Jia H, Ye Q, Qin LX, Wauthier E, Reid LM, Minato H, Honda M, Kaneko S, Tang ZY, Wang XW.

Gastroenterology. 2009 Mar;136(3):1012-24. doi: 10.1053/j.gastro.2008.12.004. Epub 2008 Dec 6.

34.

EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma.

Yamashita T, Forgues M, Wang W, Kim JW, Ye Q, Jia H, Budhu A, Zanetti KA, Chen Y, Qin LX, Tang ZY, Wang XW.

Cancer Res. 2008 Mar 1;68(5):1451-61. doi: 10.1158/0008-5472.CAN-07-6013.

35.

Identification of metastasis-related microRNAs in hepatocellular carcinoma.

Budhu A, Jia HL, Forgues M, Liu CG, Goldstein D, Lam A, Zanetti KA, Ye QH, Qin LX, Croce CM, Tang ZY, Wang XW.

Hepatology. 2008 Mar;47(3):897-907. doi: 10.1002/hep.22160.

PMID:
18176954
36.

Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma.

Yamashita T, Budhu A, Forgues M, Wang XW.

Cancer Res. 2007 Nov 15;67(22):10831-9.

37.

Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier.

Seike M, Yanaihara N, Bowman ED, Zanetti KA, Budhu A, Kumamoto K, Mechanic LE, Matsumoto S, Yokota J, Shibata T, Sugimura H, Gemma A, Kudoh S, Wang XW, Harris CC.

J Natl Cancer Inst. 2007 Aug 15;99(16):1257-69. Epub 2007 Aug 8.

PMID:
17686824
38.

Future of molecular profiling of human hepatocellular carcinoma.

Roessler S, Budhu A, Wang XW.

Future Oncol. 2007 Aug;3(4):429-39. Review.

PMID:
17661718
39.

Induction of a unique gene expression profile in primary human hepatocytes by hepatitis C virus core, NS3 and NS5A proteins.

Budhu A, Chen Y, Kim JW, Forgues M, Valerie K, Harris CC, Wang XW.

Carcinogenesis. 2007 Jul;28(7):1552-60. Epub 2007 Apr 2.

PMID:
17404395
40.

Gene expression profiling reveals potential biomarkers of human hepatocellular carcinoma.

Jia HL, Ye QH, Qin LX, Budhu A, Forgues M, Chen Y, Liu YK, Sun HC, Wang L, Lu HZ, Shen F, Tang ZY, Wang XW.

Clin Cancer Res. 2007 Feb 15;13(4):1133-9.

41.

The role of cytokines in hepatocellular carcinoma.

Budhu A, Wang XW.

J Leukoc Biol. 2006 Dec;80(6):1197-213. Epub 2006 Aug 31. Review.

PMID:
16946019
42.

Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment.

Budhu A, Forgues M, Ye QH, Jia HL, He P, Zanetti KA, Kammula US, Chen Y, Qin LX, Tang ZY, Wang XW.

Cancer Cell. 2006 Aug;10(2):99-111.

43.

Effect of hepatitis C virus core protein on the molecular profiling of human B lymphocytes.

Wu CG, Budhu A, Chen S, Zhou X, Popescu NC, Valerie K, Wang XW.

Mol Med. 2006 Jan-Mar;12(1-3):47-53.

44.

Loading and unloading: orchestrating centrosome duplication and spindle assembly by Ran/Crm1.

Budhu AS, Wang XW.

Cell Cycle. 2005 Nov;4(11):1510-4. Epub 2005 Nov 20. Review.

45.

The molecular signature of metastases of human hepatocellular carcinoma.

Budhu AS, Zipser B, Forgues M, Ye QH, Sun Z, Wang XW.

Oncology. 2005;69 Suppl 1:23-7. Epub 2005 Sep 19. Review.

PMID:
16210873
46.

Temporal and spatial control of nucleophosmin by the Ran-Crm1 complex in centrosome duplication.

Wang W, Budhu A, Forgues M, Wang XW.

Nat Cell Biol. 2005 Aug;7(8):823-30. Epub 2005 Jul 24.

PMID:
16041368
47.

Cancer-associated molecular signature in the tissue samples of patients with cirrhosis.

Kim JW, Ye Q, Forgues M, Chen Y, Budhu A, Sime J, Hofseth LJ, Kaul R, Wang XW.

Hepatology. 2004 Feb;39(2):518-27.

PMID:
14768006
48.

Mammary carcinoma suppression by cellular retinoic acid binding protein-II.

Manor D, Shmidt EN, Budhu A, Flesken-Nikitin A, Zgola M, Page R, Nikitin AY, Noy N.

Cancer Res. 2003 Aug 1;63(15):4426-33.

50.

Localization of the RAR interaction domain of cellular retinoic acid binding protein-II.

Budhu A, Gillilan R, Noy N.

J Mol Biol. 2001 Jan 26;305(4):939-49.

PMID:
11162104

Supplemental Content

Support Center